(Q34603290)

English

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19153121%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19153121%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

Rustem Khasanov

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19153121%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

author name string

Y-K Kang

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19153121%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

W-K Kang

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19153121%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

D-B Shin

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19153121%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

J Chen

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19153121%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

J Xiong

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19153121%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

J Wang

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19153121%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

M Lichinitser

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19153121%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Z Guan

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19153121%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

L Zheng

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19153121%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

M Philco-Salas

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19153121%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

T Suarez

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19153121%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

J Santamaria

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19153121%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

G Forster

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19153121%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

P I McCloud

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19153121%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

publication date

19 January 2009

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19153121%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19153121%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19153121%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19153121%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

666-673

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19153121%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN717

21 January 2018

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN717

21 January 2018

A Pilot Phase II Study of Capecitabine in Advanced or Recurrent Gastric Cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN717

21 January 2018

Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN717

21 January 2018

Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN717

21 January 2018

Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN717

21 January 2018

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN717

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN717

21 January 2018

Design and analysis of non-inferiority mortality trials in oncology.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN717

21 January 2018

Capecitabine in the treatment of advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN717

21 January 2018

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN717

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34603290&oldid=1985588626"